Physician profile
Hal Gerstein
NPI 1790874121
$16,384.27
in general payments reported to CMS, 2019-2025
57 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,776 · 2020: $1,411 · 2021: $3,987 · 2022: $3,684 · 2023: $1,801 · 2024: $1,452 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,099 · Long Term Medical Supply Or Device Loan: $250 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,098.74 |
| Long Term Medical Supply Or Device Loan | $249.99 |
| Education | $178.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,640.67 | 2019-2025 | |
| Advanced Accelerator Applications | $1,441.31 | 2019-2021 | |
| Puma Biotechnology, INC. | $1,165.03 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $1,079.70 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Janssen Biotech, INC. | $719.03 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $676.21 | 2019-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $675.40 | 2019-2025 | Jakafi |
| Tersera Therapeutics LLC | $673.53 | 2021-2025 | Xermelo, Zoladex |
| Celgene Corporation | $573.94 | 2019-2024 | Reblozyl, Pomalyst |
| Genzyme Corporation | $462.65 | 2019-2025 | |
| Lilly USA, LLC | $370.63 | 2019-2025 | Verzenio, Jaypirca |
| Amgen INC. | $356.34 | 2019-2024 | Nplate, Vectibix, Xgeva |
| Merck Sharp & Dohme LLC | $314.01 | 2019-2025 | Lynparza, Keytruda |
| Ipsen Biopharmaceuticals, INC | $307.90 | 2019-2021 | |
| Daiichi Sankyo INC. | $294.99 | 2020-2025 | Enhertu |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Gerstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.